Chester County News and Community Website
SPRING HOUSE, PA and WATERTOWN, MA — ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support the …
ChromaTan and Landmark Bio Receive NIIMBL Grant to Advance AAV Gene Therapy Manufacturing Read More
WEST CHESTER, PA — Pathways Neuro Pharma Inc. has announced a significant pivot in its development pipeline, prioritizing rare pediatric neurological disorders, with Juvenile Parkinson’s Disease (JPD) leading the charge. This …
Pathways Neuro Pharma Targets Rare Pediatric Neurological Disorders with Pioneering Gene Therapy Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More
KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb), the …
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More
PHILADELPHIA, PA — Interius BioTherapeutics has secured approval from Germany’s Paul Ehrlich Institute (PEI) to expand its pioneering INVISE Phase 1 clinical trial into Europe. This marks the first-ever clearance …
Interius BioTherapeutics Expands Groundbreaking Gene Therapy Trial to Europe Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced a groundbreaking approval of Kebilidi (eladocagene exuparvovec-tneq), marking the first gene therapy sanctioned for the treatment of aromatic L-amino …
Revolutionary Gene Therapy Approved: Kebilidi Offers New Hope for Rare Genetic Disorder Read More
BERWYN, PA — AscellaHealth has reaffirmed its commitment to Gene Therapy and Specialty Pharmacy Awareness Month for the third year, as recognized by the Society for Health Care Strategy & Market …
AscellaHealth Champions Gene Therapy and Specialty Pharmacy Awareness Month Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in its GARDian clinical trial for OCU410ST, a promising gene therapy aimed at treating Stargardt disease. The company …
Ocugen Advances Gene Therapy Trial for Stargardt Disease Read More